FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumour By Ogkologos - April 4, 2025 694 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MOTION study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Cancer Survivors Face High Rates of Housing Insecurity February 5, 2022 Dabrafenib Plus Trametinib Improves Efficacy in Children and Adolescents with Relapsed/Refractory... September 19, 2023 Modest Population-Level Increases in Survival Observed After Implementation of Immune Checkpoint... February 1, 2023 Man Born Without Legs Proves He’s Greater Than Any Obstacle He’s... December 5, 2021 Load more HOT NEWS 105-Year-Old Woman Sets Record For 100-Meter Dash Phase II LCMC3 Study of Neoadjuvant Atezolizumab Met Primary Endpoint with... Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated... Adolescent and Young Adult Cancer Survivors Face More Co-morbidity in Later...
